Bridgeway Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Bridgeway Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-74,000	Closed	-$40.2K	–	1331
2024 Q2	$40.2K	Hold	74,000	–	–	﹤0.01%	1234
2024 Q1	$75.5K	Hold	74,000	–	–	﹤0.01%	1240
2023 Q4	$42.2K	Hold	74,000	–	–	﹤0.01%	1325
2023 Q3	$77K	Sell	74,000 -51,000	-41%	-$69.2K	﹤0.01%	1262
2023 Q2	$176K	Hold	125,000	–	–	﹤0.01%	1165
2023 Q1	$199K	Hold	125,000	–	–	0.01%	1107
2022 Q4	$183K	Buy	125,000 +30,000	+32%	+$87.6K	﹤0.01%	1105
2022 Q3	$406K	Buy	95,000 +25,000	+36%	+$106K	0.01%	947
2022 Q2	$272K	Hold	70,000	–	–	0.01%	1017
2022 Q1	$333K	Buy	70,000 +35,000	+100%	+$105K	0.01%	1045
2021 Q4	$128K	Sell	35,000 -15,000	-30%	-$80K	﹤0.01%	1203
2021 Q3	$401K	Hold	50,000	–	–	0.01%	1097
2021 Q2	$567K	Buy	+50,000	New	+$502K	0.01%	1027

Other funds holding VIRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Bridgeway Capital Management's VIRX Position: Q3 2024 in Review

Bridgeway Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2024, closing a stake of 74,000 shares — an estimated $40.2K sold.

Bridgeway Capital Management first reported a position in VIRX in Q2 2021 and held it in 13 quarters. The position peaked at $567K in Q2 2021. 38 funds tracked by Wall St. Rank hold VIRX as of Q3 2024.

Bridgeway Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Bridgeway Capital Management sold 74,000 Viracta Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $40.2K.
Bridgeway Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
Bridgeway Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $567K in Q2 2021.
38 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Bridgeway Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.